Oncology trials often report on progression-free survival or overall survival, but the authors of an analysis presented during a poster session today at the European Society of Medical Oncology (ESMO) Congress argue that such endpoints are less sensitive then short-term overall response rate.
Oncology trials often report on progression-free survival (PFS) or overall survival (OS), but the authors of an analysis presented during a poster session today at the European Society of Medical Oncology (ESMO) Congress argue that such endpoints are less sensitive then short-term overall response rate (ORR) in confirming biosimilarity when long median PFS or OS are expected.
The authors presented considerations on interpreting survival data as illustrated by a sensitivity analysis from a recent study of biosimilar rituximab. In a confirmatory phase 3 study, treatment-naïve patients with follicular lymphoma received either European Medicines Agency-approved GP2013 (n = 314) or reference rituximab (n = 315).
Patients who responded to an induction treatment with cyclophosphamide, vincristine, and prednisone chemotherapy received either GP2013 or reference rituximab as maintenance monotherapy.
The primary endpoint for equivalence was ORR at the end of induction. Secondary endpoints included PFS and OS.
As of December 2016, the median follow-up was 23.6 months for the GP2013 arm and 24.2 months for the reference rituximab arm. The study met its primary endpoints to confirm biosimilarity.
Median PFS and OS could not be estimated. Hazard rations for PFS and OS were 1.31 (90% confidence interval [CI]; range, 1.02 to 1.69) and 0.77 (90% CI; range, 0.29 to 1.22), respectively.
A Kaplan-Meier analysis showed that PFS survival curves diverged between 12 and 24 months, yet the curves ran parallel outside of that period, contrary to the proportional hazard assumption of the Cox model. Complete response (CR) rates were similar between treatments at all time points, including at 33 months.
The researchers concluded that a small sample size, a low event rate, data immaturity, and other aspects of study design can decrease a study’s sensitivity in biosimilarity assessments, as demonstrated by the fact that hazard ratios for PFS and OS had opposite directions, while CR rates remained similar across time.
PFS and OS results, the authors say, should be interpreted with caution, as they may not reflect either a difference or a lack of a difference between treatments.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.